- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| EIKON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.06. | Eikon Therapeutics to join Russell 3000 index | 1 | Seeking Alpha | ||
| 25.06. | Eikon Therapeutics, Inc.: Eikon Therapeutics to Join the Russell 3000 Index | 92 | GlobeNewswire (Europe) | MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 10.06. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Eikon Therapeutics beruft Ma. Fatima Francisco in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 08.06. | Eikon Therapeutics appoints Francisco to board of directors | 1 | Investing.com | ||
| 02.06. | Cantor Fitzgerald reiterates Overweight on Eikon stock | 1 | Investing.com | ||
| 01.06. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Eikon Therapeutics, Inc.: Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology | 1 | GlobeNewswire (USA) | ||
| 21.05. | Eikon to present clinical data on three cancer programs at ASCO | 3 | Investing.com | ||
| 21.05. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology | 1 | GlobeNewswire (USA) | ||
| 11.05. | Eikon Therapeutics, Inc. reports Q1 results | 1 | Seeking Alpha | ||
| 11.05. | Eikon Therapeutics, Inc.: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates | 218 | GlobeNewswire (Europe) | Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus... ► Artikel lesen | |
| 11.05. | Eikon Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Eikon Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | Mizuho bestätigt Eikon Therapeutics nach Pipeline-Update mit "Outperform" | 5 | Investing.com Deutsch | ||
| 30.03. | Mizuho reiterates Eikon Therapeutics stock rating on pipeline update | 1 | Investing.com | ||
| 30.03. | Eikon Gains on Results | - | Baystreet.ca | ||
| 30.03. | Eikon Therapeutics GAAP EPS of -$115.29 | 1 | Seeking Alpha | ||
| 30.03. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates | 229 | GlobeNewswire (Europe) | Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4... ► Artikel lesen | |
| 30.03. | Eikon Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,152 | -1,09 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL confirms terms of CEO's Employment Agreement | ||
| EDITAS MEDICINE | 3,070 | -3,46 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,930 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,650 | -4,33 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,192 | -25,58 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,145 | +1,15 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 7,115 | -0,56 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 23,040 | +2,35 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| CEL-SCI | 1,230 | +23,00 % | CEL SCI CORP - 8-K, Current Report | ||
| CYTOKINETICS | 76,42 | +2,14 % | Cytokinetics, Incorporated: Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 | ||
| COHERUS ONCOLOGY | 1,407 | +2,85 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CURIS | 5,110 | -14,26 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.07.2026 | Das Instrument OCI US00089H1068 ACS A.DE C.ADR 1/5/EO-,50 EQUITY wird cum Kapitalmassnahme gehandelt am 03.07.2026 und ex Kapitalmassnahme am 06.07.2026 The instrument OCI US00089H1068 ACS A.DE C.ADR... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,384 | +1,96 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| FAETH THERAPEUTICS | 24,505 | +0,06 % | Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer | - Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement -
- Company changed name to Faeth... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,624 | +0,54 % | Fate Therapeutics to present FT819 data at stem cell meeting |
Das Unternehmen EIKON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,060 (-0,50 %) liegt der Kurs bei 11,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EIKON THERAPEUTICS INC finden Sie auf Wallstreet Online.